ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 分子を撃つ 神経疾患治療の新しい水平線
文献概要
多発性硬化症（MS）は中枢神経系の脱髄疾患であり，リンパ球が血液脳関門を通過し中枢神経系に侵入することで炎症が惹起されるが，α4インテグリンはこの過程の鍵となる細胞接着因子である。ナタリズマブはα4インテグリンを標的とした抗体医薬であり，MSの病態修飾療法として2014年にわが国での使用が承認された。本稿ではナタリズマブの作用機序，効果，副作用などについて最新の知見を総括する。
参考文献
1) Rivers TM, Sprunt DH, Berry GP: Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58: 39-53, 1933
2) Paterson PY: Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 111: 119-136, 1960
3) Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al: Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356: 63-66, 1992
4) Hickey WF, Hsu BL, Kimura H: T-lymphocyte entry into the central nervous system. J Neurosci Res 28: 254-260, 1991
5) Engelhardt B: Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 113: 477-485, 2006
6) Vajkoczy P, Laschinger M, Engelhardt E: α4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 105: 557-565, 2001
7) Steffen BJ, Butcher EC, Engelhardt B: Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am J Pathol 145: 189-201, 1994
8) Laschinger M, Engelhardt B: Interaction of α4-integrin with VCAM-1 is involved in adhesion of encephalogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro. J Neuroimmunol 102: 32-43, 2000
9) Laschinger M, Vajkoczy P, Engelhardt B: Encephalitogenic T cells use LFA-1 during transendothelial migration but not during capture and adhesion in spinal cord microvessels in vivo. Eur J Immunol 32: 3598-3606, 2002
10) Lyck R, Reiss Y, Gerwin N, Greenwood J, Adamson P, et al: T cell interaction with ICAM-1/ICAM-2-double deficient brain endothelium in vitro: the cytoplasmic tail of endothelial ICAM-1 is necessary for transendothelial migration of T cells. Blood 102: 3675-3683, 2003
11) Coisne C, Mao W, Engelhardt B: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 182: 5909-5913, 2009
12) Yu Y, Schürpf T, Springer TA: How natalizumab binds and antagonizes α4 integrins. J Biol Chem 288: 32314-32325, 2013
13) Tubridy N, Behan PO, Capildeo R, ChaudhuriA, Forbes R, et al: The effect of anti-α4 integrin on brain lesion activity in MS. Neurology 53: 466-472, 1999
14) Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, et al: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23, 2003
15) Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910, 2006
16) Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923, 2006
17) Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, et al: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68: 1390-1401, 2007
18) Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, et al: Early brain pseudoatrophy while on natalizumab is due to white matter volume changes. Mult Scler 19: 1175-1181, 2013
19) Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, et al: Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 7: e35843, 2012
20) Portaccio E, Stromillo ML, Goretti B, HakikiB, Giorgio A, et al: Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prosepective, non-randomized pilot study. Eur J Neurol 20: 986-990, 2013
21) Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, et al: Natalizumab treatment reduces fatigue in multiple sclerosis. PLOS ONE 8: e58643, 2013
22) O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, et al: Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 83: 78-86, 2014
23) Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Harvdova E, et al: The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69: 1391-1403, 2007
）医薬品インタビューフォーム, 2014年5月（第1版）
25) Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, et al: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368, 2005
26) Kleinschmidt-DeMasters BK, Tylers KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374, 2005
27) Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treat with natalizumab. N Engl J Med 353: 375-381, 2005
28) Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925, 2005
29) Berger JR, Houff SA, Gurwell J, Vegas N, Miller CS, et al: JC virus antibody status underestimates infection rates. Ann Neurol 74: 84-90, 2013
30) Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, et al: JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 75: 925-934, 2014
31) Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, et al: Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76: 1697-1704, 2011
32) 難病情報センター「進行性多巣性白質脳症」（http://wwwnanbyou.or.jp)
33) Ransohoff RM: Natalizumab and PML. Nat Neurosci 8: 1275, 2005
34) Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T: Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with CD49d blocking antibody natalizumab. Blood 111: 3439-3441, 2008
hematopoietic progenitor cells in humans. Blood 111: 3893-3895, 2008
cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 71: 596-602, 2014
37) Chapagain ML, Nerurkar VR: Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 202: 184-191, 2010
) prescribing information, December 2013
39) Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, et al: Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295-303, 2010
40) Lee P, Plavina T, Castro A, Berman M, Jaiswal D, et al: A second-generation ELISA (STRATIFY JCV Dx Select) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57: 141-146, 2013
41) Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, et al: Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78: 1736-1742, 2012
42) Outteryck O, Zéphir H, Salleron J, Ongagna JC, Etxeberria A, et al: JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler 20: 822-829, 2014
43) Cutter GR, Stüve O: Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 20: 1304-1305, 2014
44) Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, et al: Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study). JAMA Neurol 71: 954-960, 2014
45) Capobianco M, di Sapio A, Malentacchi M, Malucchi S, Matta M, et al: No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol ［Epub ahead of print］
46) Salhofer-Polanyi S, Baumagartner A, Kraus J, Maida E, Schmied M, et al: What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand 130: 97-102, 2014
47) Sriram S, Steiner I: Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58: 939-945, 2005
48) Steinman L, Zamvil SS: How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60: 12-21, 2006
49) Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, et al: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717, 2000
50) Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55: 458-468, 2004
51) Pirko I, Lucchinetti CF, Sriram S, Bakshi R: Gray matter involvement in multiple sclerosis. Neurology 68: 634-642, 2007
52) De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, et al: Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74: 1868-1876, 2010
53) Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, et al: The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133: 1914-1929, 2010
54) Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, et al: Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84: 1082-1091, 2013
55) Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, et al: Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res 1534: 13-21, 2013
56) Schäbitz WR, Dirnagl U: Are we ready to translate T-cell transmigration in stroke? Stroke 45: 1610-1611, 2014
掲載誌情報
